Chilean Gastric Cancer Task Force (FORCE 1)

Summary

Background. Gastric cancer (GC) is the world's second leading cause of neoplastic mortality. Genetic alterations, response to treatments and mortality rates are highly heterogeneous across different regions. In Chile, GC is the leading cause of cancer death, affecting 20 per 100,000 people and \>3,000 deaths/year. Clinical outcomes and response to "one size fits all" therapies are highly heterogeneous and thus a better stratification of patients may aid cancer treatment and response.

Study design/methods. The Gastric Cancer Task Force (GCTF) is a Chilean collaborative, non-interventional retrospective study that seeks to stratify gastric adenocarcinomas (GACs) using retrospect clinical outcomes and genomic, epigenomic and protein alterations in a cohort of 200 patients. Tumor samples from the pathology department and the Cancer Center at UC Christus healthcare network at Pontificia Universidad Católica de Chile will be analyzed using a panel of 143 known cancer genes (Oncomine Comprehensive Assay) at the Center of Excellence of Precision Medicine (CEMP) in Santiago, Chile. Additionally, gene promoter methylation will be performed and selected clinically relevant proteins (e.g. PD-L1, Erb-2, VEGFR2 among others) will be assessed by Tissue Microarray, Epstein-Barr virus (EBV) status will also be assessed. Observations will be correlated to 120 clinical parameters, including general patient information, cancer history, laboratory studies, comorbidity index, chemotherapy, targeted therapies, efficacy and follow-up.

Discussion. The development of a clinically meaningful classification that encompasses comprehensive clinical and molecular parameters may improve patient treatment, predict clinical outcomes, aid patient selection for clinical trials and offer insights into future preventive and/or therapeutic strategies.

Conditions

• Biomarkers

Sponsors & Collaborators

• Center of Excellence of Precision Medicine (CEMP)

  collaborator UNKNOWN

• Advanced Center for Chronic Diseases (ACCDiS)

  collaborator UNKNOWN

• Millennium Institute on Immunology and Immunotherapy

  collaborator OTHER

• Center UC for Investigation in Oncology (CITO)

  collaborator UNKNOWN

• Centre of Clinical Research, Health Technology Assessment Unit

  collaborator UNKNOWN

• National Scientific and Technical Research Council (CONICET), Argentina

  collaborator UNKNOWN

• Grupo Oncologico Cooperativo del Sur (GOCS), Argentina

  collaborator UNKNOWN

• Hospital Universitario central de Asurias, Oviedo, España

  collaborator UNKNOWN

• Hospital Morales Meseger, Murcia, España

  collaborator UNKNOWN

• Centro de Cancer. Pontificia Universidad Católica de Chile

  collaborator UNKNOWN

• Hematology and Oncology Department

  collaborator UNKNOWN

• Pontificia Universidad Catolica de Chile

  lead OTHER

Principal Investigators

• Marcelo Garrido, MD · Pontificia Universidad Catolica de Chile

Eligibility

Min Age

18 Years

Max Age

99 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-01-01

Primary Completion

2018-04-30

Completion

2019-01-01

Countries

• Chile

Study Locations